Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Net prices that health plans paid for medicines rose a modest 0.4% in the fourth quarter, but that compared unfavorably with ...

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due ...

Talks between CMS and drugmaker Amgen authorized under the Inflation Reduction Act (IRA), former President Biden's signature ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

The following is a list of major prescription drugs whose ingredients or components are imported into the United States from the European Union, based on U.S. Food and Drug Administration import data ...

If left unchecked, the power of PBMs and their complex relationships within the American healthcare system could lead to higher drug costs and diminished returns.

AbbVie Inc. stands out as one of the top pharma stocks to buy, according to hedge funds. The company exceeded analyst ...

While Humira’s 2023 loss of exclusivity hung over AbbVie’s head for years, the ascent of the Chicago drugmaker’s immunology successors Skyrizi and Rinvoq under prior CEO Richard Gonzalez has swiftl | ...

Weight loss drug market projected to reach $130 billion in sales ... It also comes after the patent for AbbVie’s autoimmune medicine, Humira, expires. How to check your state tax refund status ...

The company trying to enter the obesity market does not change that assessment because when the obesity drug(s) of AbbVie will contribute to revenue, it is not the Humira sales that need to be ...